An Engineered Cytokine Receptor for Enhanced CAR T cells
A chimeric cytokine receptor to augment CAR T-cell function
Sustained activation of CAR T cells requires the presence of immune stimulatory cytokines. The suppressive microenvironment in solid tumorslacks soluble cytokines. While systemic administration of stimulatory cytokines can be beneficial for CAR T cell function, this has led to toxicities in clinical trials and is therefore not therapeutically viable. To confer the benefits of cytokine supplementation to CAR T cell therapy without incurring systemic toxicity, Dr. Michael Jensen and colleagues have developed an engineered cytokine receptor called CCRIL21. T cells expressing CCRIL21 recapitulated the effects of IL-21 expression in vitro in the absence of soluble IL-21. These T cells demonstrated prolonged survival and proliferation. CAR T cells expressing CCRIL21 had improved therapeutic efficacy in a mouse model of glioblastoma. CCRIL21 provides ligand independent cytokine stimulation to CAR T cells and improves CAR T cell function in solid tumors.
- Adjuvant for CAR T cell therapy
- CAR T cell therapy for solid tumors
- Ligand independent cytokine stimulation
- Regulatable receptor expression
Global CAR T cell therapy market was valued at USD 467 million in 2018 and is expected to reach USD 2.9 billion by 2023, growing at a CAGR of 44.1%. Solid tumors account for more than 80% of cancers. About 1.7 million new cancer cases are estimated in 2019. There are over 20 active clinical trials investigating CAR T cell therapy in solid tumors. There are no approved solid tumor targeting CAR T cell therapies in the market.
Cell therapy Therapeutic
Preclinical in vivo
Michael Jensen, MD
To learn more about this technology, please email Kamya Rajaram.